Illumina, Inc. $ILMN Shares Purchased by US Bancorp DE

Key Points

• US Bancorp DE increased its stake in Illumina by 43.5% during the second quarter, now owning 31,151 shares valued at approximately $2.97 million.
• Illumina reported earnings of $1.19 per share, exceeding estimates of $1.02, but quarterly revenue declined by 4.8% year-over-year.
• The company has a current consensus rating of "Hold" from analysts, with an average target price of $123.56 per share.

US Bancorp DE lifted its stake in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) by 43.5% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 31,151 shares of the life sciences company's stock after purchasing an additional 9,436 shares during the period. US Bancorp DE's holdings in Illumina were worth $2,972,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in ILMN. Allegiance Financial Group Advisory Services LLC acquired a new position in Illumina during the second quarter worth $344,000. Aurora Investment Managers LLC. boosted its position in shares of Illumina by 1.3% during the 2nd quarter. Aurora Investment Managers LLC. now owns 15,258 shares of the life sciences company's stock valued at $1,456,000 after acquiring an additional 192 shares during the last quarter. KLP Kapitalforvaltning AS boosted its position in shares of Illumina by 14.4% during the 2nd quarter. KLP Kapitalforvaltning AS now owns 69,845 shares of the life sciences company's stock valued at $6,664,000 after acquiring an additional 8,800 shares during the last quarter. Valeo Financial Advisors LLC boosted its position in shares of Illumina by 43.4% during the 2nd quarter. Valeo Financial Advisors LLC now owns 3,643 shares of the life sciences company's stock valued at $348,000 after acquiring an additional 1,102 shares during the last quarter. Finally, Wealthcare Advisory Partners LLC boosted its position in shares of Illumina by 41.1% during the 2nd quarter. Wealthcare Advisory Partners LLC now owns 8,916 shares of the life sciences company's stock valued at $851,000 after acquiring an additional 2,598 shares during the last quarter. 89.42% of the stock is currently owned by institutional investors and hedge funds.

Illumina Price Performance

ILMN opened at $91.00 on Wednesday. The firm has a market cap of $13.99 billion, a price-to-earnings ratio of 11.52, a PEG ratio of 2.29 and a beta of 1.40. Illumina, Inc. has a 12-month low of $68.70 and a 12-month high of $156.66. The company has a current ratio of 1.81, a quick ratio of 1.41 and a debt-to-equity ratio of 0.66. The stock's 50-day moving average price is $98.13 and its 200 day moving average price is $90.43.

Illumina (NASDAQ:ILMN - Get Free Report) last released its earnings results on Thursday, July 31st. The life sciences company reported $1.19 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.02 by $0.17. The company had revenue of $1.06 billion for the quarter, compared to analyst estimates of $1.12 billion. Illumina had a net margin of 29.36% and a return on equity of 28.93%. The firm's quarterly revenue was down 4.8% on a year-over-year basis. During the same period in the prior year, the business earned $0.36 EPS. Illumina has set its FY 2025 guidance at 4.450-4.55 EPS. As a group, sell-side analysts expect that Illumina, Inc. will post 4.51 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on the stock. Stephens set a $110.00 target price on shares of Illumina and gave the company an "overweight" rating in a report on Monday, August 4th. Wall Street Zen cut Illumina from a "buy" rating to a "hold" rating in a report on Saturday, August 2nd. Daiwa Capital Markets cut Illumina from an "outperform" rating to a "neutral" rating and set a $94.00 price objective on the stock. in a report on Tuesday, August 12th. Weiss Ratings reaffirmed a "sell (d+)" rating on shares of Illumina in a research note on Wednesday, October 8th. Finally, Daiwa America lowered Illumina from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, August 12th. Six research analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and three have given a Sell rating to the company. According to MarketBeat, Illumina currently has a consensus rating of "Hold" and an average target price of $123.56.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.